NEW YORK (GenomeWeb News) – Novo Nordisk has licensed gene expression technology from TET Systems for use in its research activities, TET Systems said.
Under the agreement, Novo Nordisk will use TET Systems technology at the Hagedorn Research Institute, which handles the drug developer's internal research activities.
Heidelberg, Germany-based TET Systems holds six patent families of intellectual property covering methods to control gene expression in higher organisms.
Financial terms of the agreement were not released.